Investing.com – Boston Scientific Corporation reported income and benefits of the first quarter that exceeded the expectations of analysts, promoting their shares 3.2% in Wednesday’s first operations.
The medical devices manufacturer registered a adjusted benefit of $ 0.75 for the first quarter of 2025, exceeding the estimate of consensus of $ 0.67. The income reached 4,660 million dollars, above the expectations of 4,570 million dollars and representing an increase of 20.9% year -on -year.
Boston Scientific (NYSE: BSX) experienced solid growth in all its business segments. Cardiovascular sales increased 26.2% year -on -year to 3,090 million dollars, while Medsurg revenues rose 11.7% to 1,580 million dollars.
“We have achieved an exceptional quarter to begin the year, reflecting the effectiveness of our highly committed global team and the strength of our product portfolio,” said Mike Mahoney, president and executive director of Boston Scientific.
-The company raised its adjusted BPA forecast for the entire 2025 to a range of 2.87 to $ 2.94 from 2.80-2.87 dollars, also above the consensus of analysts of 2.86 dollars. Wait for an organic growth of income from 12% to 14% for the year.
For the second quarter of 2025, Boston Scientific projects an organic growth of income from 13% to 15% and an adjusted BPA between 0.71 and $ 0.73.
“We have achieved an exceptional quarter to begin the year, reflecting the effectiveness of our highly committed global team and the strength of our product portfolio,” said Mike Mahoney, president and executive director of Boston Scientific. “We remain well positioned for the future while we continue focusing attention on significant innovation, clinical science and the execution of our category leadership strategy to boost differentiated growth and long -term performance.”
-
Would you like to know how investors organize your most successful investors? InvestingPro gives access to the strategies and wallets of the best investors. In addition, you will receive more than 100 value recommendations based on analysis backed by AI. Do you feel curious? Click here for more information.
